A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACCCHAU, N. G; HOTTE, S. J; CHEN, E. X et al.Annals of oncology. 2012, Vol 23, Num 6, pp 1562-1570, issn 0923-7534, 9 p.Article

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckABDUL RAZAK, A. R; SOULIERES, D; CHAN, K. K et al.Annals of oncology. 2013, Vol 24, Num 3, pp 761-769, issn 0923-7534, 9 p.Article

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07aCHI, K. N; BEARDSLEY, E; EIGL, B. J et al.Annals of oncology. 2012, Vol 23, Num 1, pp 53-58, issn 0923-7534, 6 p.Article

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)SAHEBJAM, S; BEDARD, P. L; KAMEL-REID, S et al.British journal of cancer. 2013, Vol 109, Num 4, pp 943-949, issn 0007-0920, 7 p.Article

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerCHIT, K. N; ELLARD, S. L; WALSH, W et al.Annals of oncology. 2008, Vol 19, Num 4, pp 746-751, issn 0923-7534, 6 p.Article

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumoursRAZAK, Ara; HOTTE, S. J; ZHU, J et al.British journal of cancer. 2011, Vol 104, Num 5, pp 756-762, issn 0007-0920, 7 p.Article

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers : a Princess Margaret Hospital Phase II Consortium studyHOTTE, S. J; OZA, A; WINQUIST, E. W et al.Annals of oncology. 2006, Vol 17, Num 2, pp 334-340, issn 0923-7534, 7 p.Article

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsMOORE, M; HIRTE, H. W; SIU, L et al.Annals of oncology. 2005, Vol 16, Num 10, pp 1688-1694, issn 0923-7534, 7 p.Article